Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

Cuili Fan

Shanghai HEP Pharmaceutical CO, Ltd, Shanghai, China

Biography

Dr.  Cuili Fan is currently working in Shanghai HEP Pharmaceutical CO, Ltd, Shanghai, China. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work. 

Publications
  • Short Communication   
    Regulation of Bile Acids by an NTCP Inhibitor is Promising for the Treatment of Nonalcoholic Steatohepatitis
    Author(s): Cuili Fan, Hongli Liu* and Jian Wu*

    The beneficial effects of Hepalatide, an inhibitor of sodium taurocholate cotransporting polypeptide (NTCP), on the progression of nonalcoholic steato hepatitis was previously validated in mice. The underlying mechanismsare presumably associated with the profile changes of bile acids, which are natural agonistsfor FXR and TGR5receptors. In this short communication, the profile of bile acids and the metabolic changes in the liver or peripheral tissues were analyzed. It is our anticipation that using NTCP inhibitors, such as Hepalatide for the nonalcoholic steatohepatitis would be a clinically-applicable strategy.. View More»
    DOI: 10.35248/2167-0870.20.10.420

    Abstract HTML PDF

Top